Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 4/2010

01-04-2010 | Original Article

Levels of Soluble CD40 Ligand and P-Selectin in Nonalcoholic Fatty Liver Disease

Authors: Cemal Nuri Ercin, Teoman Dogru, Serkan Tapan, Yıldırım Karslioglu, Cem Haymana, Selim Kilic, Alper Sonmez, Zeki Yesilova, Ahmet Uygun, Mustafa Gulsen, Sait Bagci, M. Kemal Erbil

Published in: Digestive Diseases and Sciences | Issue 4/2010

Login to get access

Abstract

Nonalcoholic fatty liver disease (NAFLD) is linked to an increased risk of cardiovascular disease. We aimed to research whether the levels of soluble P-selectin (sP-selectin) and soluble CD40 ligand (sCD40L), markers of endothelial function, are altered in subjects with NAFLD having no confounding factors for atherosclerosis. sCD40L, sP-selectin, and high-sensitivity C-reactive protein (hsCRP) levels, and homeostasis model assessment of insulin resistance (HOMA-IR) indexes were measured in 50 NAFLD subjects and 30 healthy controls. sCD40L, sP-selectin, and hsCRP levels were not significantly different between two groups (P = 0.48, 0.51, and 0.34, respectively). Body mass index, waist circumference, and insulin levels and HOMA indexes were significantly higher in subjects with NAFLD (all P < 0.001). The present data show that sCD40L and sP-selectin may not contribute to the accelerated atherogenesis associated with this clinically relevant condition.
Literature
1.
2.
Preiss D, Sattar N. Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115:141–150. doi:10.​1042/​CS20070402.CrossRef
3.
4.
5.
Targher G, Bertolini L, Scala L, Zoppini G, Zenari L, Falezza G. Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue. Dia Med. 2005;22:1354–1358. doi:10.​1111/​j.​1464-5491.​2005.​01646.​x.CrossRef
6.
7.
Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis. 2009;203:581–586.CrossRefPubMed
8.
Targher G, Bertolini L, Rodella S, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care. 2007;30:2119–2121. doi:10.​2337/​dc07-0349.CrossRefPubMed
9.
10.
11.
12.
Aukrust P, Müller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999;100:614–620.PubMed
13.
14.
15.
Wagner DD. The Weibel-Palade body: The storage granule for von Willebrand factor and P-selectin. Thromb Haemost. 1993;70:105–110.PubMed
16.
Lip GY, Blann AD, Zarifis J, Beevers M, Lip PL, Beevers DG. Soluble adhesion molecule P-selectin and endothelial dysfunction in essential hypertension: İmplications for atherogenesis? A preliminary report. J Hypertens. 1995;13:1674–1678.PubMed
17.
Davì G, Romano M, Mezzetti A, et al. Increased levels of soluble P-selectin in hypercholesterolemic patients. Circulation. 1998;97:953–957.PubMed
18.
Blann AD, Dobrotova M, Kubisz P, McCollum CN. Von Willebrand factor, soluble P-selectin, tissue plasminogen activator and plasminogen activator inhibitor in atherosclerosis. Thromb Haemost. 1995;74:626–630.PubMed
19.
Ikeda H, Takajo Y, Ichiki K, et al. Increased soluble form of P-selectin in patients with unstable angina. Circulation. 1995;92:1693–1696.PubMed
20.
Sakurai S, Inoue A, Koh CS, Owa M, Yanagisawa N. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc Med. 1997;2:163–168.PubMed
21.
22.
Ridker PM, Buring JE, Rifai N. Soluble P-selectin and the risk of future cardiovascular events. Circulation. 2001;103:491–495.PubMed
23.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.PubMed
24.
Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419. doi:10.​1007/​BF00280883.CrossRefPubMed
25.
Bonora E, Targher G, Alberiche M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000;23:57–63. doi:10.​2337/​diacare.​23.​1.​57.CrossRefPubMed
26.
27.
28.
Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: Role of visceral fat accumulation. Diabetes Care. 2004;27:2498–2500. doi:10.​2337/​diacare.​27.​10.​2498.CrossRefPubMed
29.
30.
31.
32.
Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001;58:41–43.
33.
Karmann K, Hughes CC, Schechner J, Fanslow WC, Pober JS. CD40 on human endothelial cells: Inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci USA. 1995;92:4342–4346. doi:10.​1073/​pnas.​92.​10.​4342.CrossRefPubMed
34.
35.
Mach F, Sauty A, Iarossi AS, et al. Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. J Clin Invest. 1999;104:1041–1050. doi:10.​1172/​JCI6993.CrossRefPubMed
36.
Denger S, Jahn L, Wende P, et al. Expression of monocyte chemoattractant protein-1 cDNA in vascular smooth muscle cells: Induction of the synthetic phenotype: A possible clue to SMC differentiation in the process of atherogenesis. Atherosclerosis. 1999;144:15–23. doi:10.​1016/​S0021-9150(99)00033-7.CrossRefPubMed
37.
Mach F, Schönbeck U, Bonnefoy JY, Pober JS, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: Induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396–399.PubMed
38.
Schönbeck U, Mach F, Sukhova GK, et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol. 2000;156:7–14.PubMed
39.
40.
41.
McEver RP. Properties of GMP-140, an inducible granule membrane protein of platelets and endothelium. Blood Cells. 1990;16:73–80.PubMed
42.
Tedder TF, Steeber DA, Chen A, Engel P. The selectins: Vascular adhesion molecules. FASEB J. 1995;9:866–873.PubMed
43.
Berman CL, Yeo EL, Wencel-Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest. 1986;78:130–137. doi:10.​1172/​JCI112542.CrossRefPubMed
44.
45.
Parmentier S, McGregor L, Catimel B, Leung LL, McGregor JL. Inhibition of platelet functions by a monoclonal antibody (LYP20) directed against a granule membrane glycoprotein (GMP-140/PADGEM). Blood. 1991;77:1734–1739.PubMed
46.
47.
48.
Blann AD, Seigneur M, Boisseau MR, Taberner DA, McCollum CN. Soluble P selectin in peripheral vascular disease: Relationship to the location and extent of atherosclerotic disease and its risk factors. Blood Coagul Fibrinolysis. 1996;7:789–793. doi:10.​1097/​00001721-199611000-00008.CrossRefPubMed
49.
Aller R, de Luis DA, Fernandez L, et al. Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease. Dig Dsi Sci. 2008;53:1088–1092. doi:10.​1007/​s10620-007-9981-3.CrossRef
50.
51.
52.
53.
Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, González R, Alvarez M, Hernández V, García-Zattera MJ, Otarola F, Medina B, Rigotti A, Miquel JF, Marshall G, Nervi F. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009;29:82–88.CrossRefPubMed
54.
Derosa G, Fogari E, Cicero AF, et al. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. Hypertens Res. 2007;30:387–394. doi:10.​1291/​hypres.​30.​387.CrossRefPubMed
55.
Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002;48:877–883.PubMed
Metadata
Title
Levels of Soluble CD40 Ligand and P-Selectin in Nonalcoholic Fatty Liver Disease
Authors
Cemal Nuri Ercin
Teoman Dogru
Serkan Tapan
Yıldırım Karslioglu
Cem Haymana
Selim Kilic
Alper Sonmez
Zeki Yesilova
Ahmet Uygun
Mustafa Gulsen
Sait Bagci
M. Kemal Erbil
Publication date
01-04-2010
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 4/2010
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-009-0817-1

Other articles of this Issue 4/2010

Digestive Diseases and Sciences 4/2010 Go to the issue

Correspondence

Glutaraldehyde-Induced Chemical Colitis Versus Ischemic Colitis

Original Article

Proteasome Inhibitor MG132 Inhibits Angiogenesis in Pancreatic Cancer by Blocking NF-κB Activity

Original Article

Genetic Polymorphisms of CYP2D6 Oxidation in Patients with Inflammatory Bowel Disease

Original Article

Frequency and Factors Associated with Small Intestinal Bacterial Overgrowth in Patients with Cirrhosis of the Liver and Extra Hepatic Portal Venous Obstruction

Original Article

Increased Oxidative Stress, Decreased Total Antioxidant Capacity, and Iron Overload in Untreated Patients with Chronic Hepatitis C

Original Article

Laparotomy Attenuates Lipopolysaccharide-Induced Gastric Bleeding in the Rat
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits